Suppr超能文献

巨细胞性主动脉炎患者升主动脉瘤的外科治疗

Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis.

作者信息

Zehr Kenton J, Mathur Alok, Orszulak Thomas A, Mullany Charles J, Schaff Hartzell V

机构信息

Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA.

出版信息

Ann Thorac Surg. 2005 May;79(5):1512-7. doi: 10.1016/j.athoracsur.2004.10.039.

Abstract

BACKGROUND

Giant cell aortitis is a rare cause of ascending aortic aneurysm disease despite giant cell arteritis being a common cause of vasculitis. We evaluated an 8-year experience with surgical repair with regard to preoperative variables, extent of disease, required surgical procedures, and the propensity to develop additional great vessel aneurysms.

METHODS

Thirty-seven patients (29 female, 8 male; aged 69.6 +/- 9.5 years) were operated on from 1995 to 2002. Ten (27%) patients had a history of steroid treatment for temporal arteritis or polymyalgia rheumatica 8.9 +/- 3.9 years before. Nineteen (51%) patients had +3 or +4 aortic regurgitation. Maximal aneurysm size was 6.1 +/- 0.8 cm. Thirty (81%) patients underwent polyethylene terephthalate fiber (Dacron) tube graft replacement of the ascending aorta, 4 (11%) had a modified Bentall procedure, 2 (5%) had a valve-sparing aortic root reconstruction, and 1 (3%) had aortorrhaphy. Twenty-two (59%) patients required 22 +/- 9 minutes of hypothermic circulatory arrest for hemiarch or complete aortic arch replacement. Twenty-six (70%) patients had concomitant cardiac procedures.

RESULTS

There was no early mortality. Morbidity was reexploration for bleeding in 3 (8%) patients, stroke in 3 (8%), left vocal cord paralysis in 2 (5%), renal failure in 2 (5%), and gastrointestinal bleeding in 1 (3%). Mean follow-up was 2.8 +/- 2.3 years. Four-year actuarial survival was 74% (95% confidence interval, 57% to 94%). Other descending or abdominal aortic or great vessel aneurysms occurred in 17 (46%) patients. Four patients had prior aneurysm surgery, 8 are monitored with aneurysms, and 5 underwent repair of an aneurysm in the follow-up period. Of 8 late deaths, 3 were caused by complications of a descending thoracic aneurysm. No patient required replacement of a native aortic valve that was preserved during the initial operative procedure.

CONCLUSIONS

Ascending aortic aneurysms caused by giant cell aortitis can involve the aorta from the aortic root through the aortic arch, thus requiring a tailored operative approach. The aortic valve tissue is spared from the pathologic process. Other aneurysms of the aorta and great vessels occur in nearly half of patients. Frequent surveillance of the remaining aorta is mandatory.

摘要

背景

尽管巨细胞动脉炎是血管炎的常见病因,但巨细胞性主动脉炎却是升主动脉瘤疾病的罕见病因。我们评估了8年的手术修复经验,涉及术前变量、疾病范围、所需手术操作以及发生额外大血管动脉瘤的倾向。

方法

1995年至2002年期间,对37例患者(29例女性,8例男性;年龄69.6±9.5岁)进行了手术。10例(27%)患者在8.9±3.9年前有颞动脉炎或风湿性多肌痛的类固醇治疗史。19例(51%)患者有+3或+4级主动脉瓣反流。最大动脉瘤大小为6.1±0.8厘米。30例(81%)患者接受了聚对苯二甲酸乙二酯纤维(涤纶)人工血管置换升主动脉,4例(11%)接受了改良Bentall手术,2例(5%)接受了保留瓣膜的主动脉根部重建,1例(3%)接受了主动脉修补术。22例(59%)患者因半弓或全主动脉弓置换需要22±9分钟的低温循环停止。26例(70%)患者同时进行了心脏手术。

结果

无早期死亡。并发症包括3例(8%)患者因出血再次手术、3例(8%)患者发生中风、2例(5%)患者左声带麻痹、2例(5%)患者肾衰竭和1例(3%)患者胃肠道出血。平均随访时间为2.8±2.3年。四年精算生存率为74%(95%置信区间,57%至94%)。17例(46%)患者发生了其他降主动脉、腹主动脉或大血管动脉瘤。4例患者曾接受过动脉瘤手术,8例患者有动脉瘤并接受监测,5例患者在随访期间接受了动脉瘤修复。在8例晚期死亡中,3例由降胸段动脉瘤并发症引起。没有患者需要更换初次手术中保留的自体主动脉瓣。

结论

巨细胞性主动脉炎引起的升主动脉瘤可累及从主动脉根部到主动脉弓的主动脉,因此需要采用量身定制的手术方法。主动脉瓣组织未受病理过程影响。近一半的患者会发生主动脉和大血管的其他动脉瘤。必须对剩余的主动脉进行频繁监测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验